Deprecated: Required parameter $field follows optional parameter $value in /customers/6/e/3/senatormedical.se/httpd.www/wp-content/plugins/stm-gdpr-compliance/includes/plugins/GravityForms.php on line 142
Warning: Cannot modify header information - headers already sent by (output started at /customers/6/e/3/senatormedical.se/httpd.www/wp-content/plugins/stm-gdpr-compliance/includes/plugins/GravityForms.php:142) in /customers/6/e/3/senatormedical.se/httpd.www/wp-includes/feed-rss2.php on line 8
Is an emerging treatment modality for cancer patients which can effectively reduce tumour burden and induce immunogenic cell death. Electrochemotherapy is most commonly used with bleomycin as the drug of choice, here we examine the efficacy of electrochemotherapy with cisplatin. Electrochemotherapy with cisplatin was found to effectively reduce tumour growth in a range of murine models and induce significant intratumoural recruitment of myeloid and humoral immune cells. Following the observations of immune system mobilisation, we have shown an ability of electrochemotherapy to reduce metastatic potential as determined by tumour burden in the lung, and to exert an abscopal effect by reducing growth at distal untreated secondary tumours. • ECT with cisplatin is an effective form of therapy showing significant decrease in cancer cell growth in vitro and in vivo.• • Immune cell mobilisation is visible locally and systemically following treatment.• • ECT with cisplatin may be useful in reducing the growth of distal untreated growth and controlling metastatic disease. Read the entire article on this LINK Reference: Volume 442, 1 February 2019, Pages 475-482Highlights
Cancer Letters
Electrochemotherapy delivers short, intense pulses of electricity to a tumour, which temporarily increase how porous cancer cells are, allowing more drugs to flood inside.
The technique is currently used to treat skin cancers and some breast cancers, which can easily be reached by the electrodes needed to deliver the pulses of electricity.
Researchers at CancerResearch@UCC have found that a technique known as electrochemotherapy causes pancreatic cancer cells to become more sensitive to three widely used anti-cancer drugs.
With PCRF funding, Dr Patrick Forde – who led the research – is investigating whether it can be used for tumours in the pancreas, deep inside the body.
The results also revealed that the cells died in a specific way that may have implications for how the immune system responds to the cancer cells after the drug treatment.
Keywords: #electrochemotherapy #pancreatic cancer
Reference: Read full article
]]>